fda warning letters compounded semaglutide tirzepatide 2025 Drugmakers battle pharmacies over Ozempic and Zepbound : Shots There's lots going on this

The choice between medication-first (Remedy Meds) and behavior-first (Noom) depends on clinical presentation, metabolic urgency, psychological readiness, and individual preference

Semaglutide, the active ingredient in Ozempic, is one of the most potent GLP-1 receptor agonists and may be a first-line option, especially in people with heart disease or obesity

Off-label coverage for weight loss is uncommon

With decades of expertise in diabetes and metabolic disorders, the company turned its innovation engine toward tackling obesity

The researchers published their findings on June 25 in the journal Experts say that loss of smell or taste from GLP-1 medications doesnt appear to be widespread

Rural areas, in particular, often experience longer delays due to the additional challenges of transporting and storing temperature-sensitive medications